Colorectal tumor vascularity: quantitative assessment with multidetector CT--do tumor perfusion measurements reflect angiogenesis?

PURPOSE To establish the relationships between quantitative perfusion computed tomography (CT) parameters-specifically, primary tumor blood flow, blood volume, transit time, and permeability surface-area product-and immunohistologic markers of angiogenesis in colorectal cancer. MATERIALS AND METHODS After institutional review board approval and informed patient consent were obtained for this prospective study, 23 patients (11 men, 12 women; mean age, 68.4 years; age range, 34.8-87.1 years) with colorectal adenocarcinoma underwent a 65-second perfusion CT examination, and tumor blood flow, blood volume, mean transit time, and permeability surface-area product were determined. After surgery, resected specimens were sectioned and stained immunohistochemically to identify CD34 for quantification of microvessel density (MVD), to identify smooth muscle actin for assessment of pericyte coverage index, to identify vascular endothelial growth factor (VEGF), and to identify glucose transporter protein (GLUT-1). Perfusion CT measurements were correlated with MVD, pericyte coverage index, VEGF expression, and GLUT-1 expression by using Pearson or Spearman rank correlation analysis, with significance assigned at the 5% level. RESULTS Mean blood flow, blood volume, transit time, and permeability surface-area product values were 72.1 mL/min/100 g of tissue +/- 28.4 (standard deviation), 6.2 mL/100 g of tissue +/- 1.4, 9.3 seconds +/- 3.9, and 13.9 mL/min/100 g of tissue +/- 3.2, respectively. Blood volume (r = 0.59, P = .002) and permeability surface-area product (r = 0.46, P = .03) correlated positively with MVD, but blood flow (r = 0.27, P = .22) and transit time (r = -0.18, P = .44) did not. There were no significant associations between any perfusion CT parameter and pericyte coverage index (r <or= 0.36, P > .05), VEGF score (rho <or= 0.30, P >or= .15), or GLUT-1 score (rho < 0.21, P >or= .33). CONCLUSION Tumor permeability surface-area product and blood volume correlate positively with MVD and may reflect the microvascularity of colorectal tumors.

[1]  R. Airley,et al.  Glucose transporter glut-1 expression correlates with tumor hypoxia and predicts metastasis-free survival in advanced carcinoma of the cervix. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[2]  V. Goh,et al.  Quantitative assessment of colorectal cancer perfusion using MDCT: inter- and intraobserver agreement. , 2005, AJR. American journal of roentgenology.

[3]  Martijn R. Meijerink,et al.  The use of perfusion CT for the evaluation of therapy combining AZD2171 with gefitinib in cancer patients , 2007, European Radiology.

[4]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[5]  J A Beliën,et al.  Fully automated microvessel counting and hot spot selection by image processing of whole tumour sections in invasive breast cancer. , 1999, Journal of clinical pathology.

[6]  Ting-Yim Lee,et al.  An Adiabatic Approximation to the Tissue Homogeneity Model for Water Exchange in the Brain: I. Theoretical Derivation , 1998, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[7]  K. Haruma,et al.  Clinical Significance of Human Erythrocyte Glucose Transporter 1 Expression at the Deepest Invasive Site of Advanced Colorectal Carcinoma , 2001, Oncology.

[8]  Zi-Ping Li,et al.  Tumor angiogenesis and dynamic CT in colorectal carcinoma: radiologic-pathologic correlation. , 2005, World journal of gastroenterology.

[9]  R. Airley,et al.  Glucose transporter-1 (GLUT-1): a potential marker of prognosis in rectal carcinoma? , 2003, British Journal of Cancer.

[10]  C. Yi,et al.  Solitary pulmonary nodules: dynamic enhanced multi-detector row CT study and comparison with vascular endothelial growth factor and microvessel density. , 2004, Radiology.

[11]  D. Sahani,et al.  Assessing tumor perfusion and treatment response in rectal cancer with multisection CT: initial observations. , 2005, Radiology.

[12]  Masahiko Kusumoto,et al.  Contrast‐enhanced dynamic computed tomography for the evaluation of tumor angiogenesis in patients with lung carcinoma , 2002, Cancer.

[13]  H. Augustin,et al.  Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. , 2000, Cancer research.

[14]  Brian H. Mayall,et al.  Re: Tumor Angiogenesis as a Prognostic Assay for Invasive Ductal Breast Carcinoma , 1995 .

[15]  V. Goh,et al.  Quantitative colorectal cancer perfusion measurement by multidetector-row CT: does greater tumour coverage improve measurement reproducibility? , 2006, The British journal of radiology.

[16]  Ricky T. Tong,et al.  Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer , 2004, Nature Medicine.

[17]  H. Nielsen,et al.  Soluble vascular endothelial growth factor levels in patients with primary colorectal carcinoma , 2000 .

[18]  James L Tatum,et al.  Hypoxia: Importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy , 2006, International journal of radiation biology.

[19]  Steve Halligan,et al.  Quantitative Colorectal Cancer Perfusion Measurement Using Dynamic Contrast-Enhanced Multidetector-Row Computed Tomography: Effect of Acquisition Time and Implications for Protocols , 2005, Journal of computer assisted tomography.

[20]  Steve Halligan,et al.  Quantitative tumor perfusion assessment with multidetector CT: are measurements from two commercial software packages interchangeable? , 2007, Radiology.

[21]  A. Harris,et al.  The relationship of the neo-angiogenic marker, endoglin, with response to neoadjuvant chemotherapy in breast cancer , 2006, British Journal of Cancer.

[22]  H. Karakas,et al.  Dynamic MRI in indirect estimation of microvessel density, histologic grade, and prognosis in colorectal adenocarcinomas , 2004, Abdominal Imaging.

[23]  J. Overgaard,et al.  Quantification of angiogenesis as a prognostic marker in human carcinomas: a critical evaluation of histopathological methods for estimation of vascular density. , 2003, European journal of cancer.

[24]  Philippe Lambin,et al.  Tumor perfusion rate determined noninvasively by dynamic computed tomography predicts outcome in head-and-neck cancer after radiotherapy. , 2003, International journal of radiation oncology, biology, physics.

[25]  P. Hahnfeldt,et al.  Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. , 2002, Journal of the National Cancer Institute.

[26]  M Gion,et al.  Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumours. , 2002, European journal of cancer.

[27]  D J Collins,et al.  Dynamic contrast‐enhanced magnetic resonance imaging is a poor measure of rectal cancer angiogenesis , 2006, The British journal of surgery.

[28]  R. Kerbel,et al.  Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. , 1995, Cancer research.

[29]  J. Folkman,et al.  Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma. , 1991, The New England journal of medicine.

[30]  Yu Wang,et al.  Dynamic CT Evaluation of Tumor Vascularity in Renal Cell Carcinoma. , 2006, AJR. American journal of roentgenology.

[31]  J. Folkman,et al.  Fundamental concepts of the angiogenic process. , 2003, Current molecular medicine.

[32]  R. Benamouzig,et al.  Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature , 2005, British Journal of Cancer.

[33]  A. Padhani,et al.  Non‐invasive methods of assessing angiogenesis and their value in predicting response to treatment in colorectal cancer , 2001, The British journal of surgery.

[34]  J. Hennig,et al.  PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging. , 2002, Cancer research.

[35]  Vicky Goh,et al.  Tumor antivascular effects of radiotherapy combined with combretastatin a4 phosphate in human non-small-cell lung cancer. , 2007, International journal of radiation oncology, biology, physics.

[36]  M A Konerding,et al.  3D microvascular architecture of pre-cancerous lesions and invasive carcinomas of the colon , 2001, British Journal of Cancer.

[37]  P. V. van Diest,et al.  Heterogeneity and reproducibility of microvessel counts in breast cancer. , 1995, Laboratory investigation; a journal of technical methods and pathology.

[38]  Vicky Goh,et al.  Effect of nitric-oxide synthesis on tumour blood volume and vascular activity: a phase I study. , 2007, The Lancet. Oncology.

[39]  Lee M Ellis,et al.  Functional CT for quantifying tumor perfusion in antiangiogenic therapy in a rat model. , 2005, Radiology.

[40]  J. Takita,et al.  Glut-1 glucose transporter expression in esophageal squamous cell carcinoma is associated with tumor aggressiveness. , 2002, Anticancer research.

[41]  V. Goh,et al.  Quantitative assessment of tissue perfusion using MDCT: comparison of colorectal cancer and skeletal muscle measurement reproducibility. , 2006, AJR. American journal of roentgenology.

[42]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[43]  S. Maeda,et al.  K-ras gene mutation related to histological atypias in human colorectal adenomas. , 1995, Biotechnic & histochemistry : official publication of the Biological Stain Commission.

[44]  J. Folkman.  Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.